Novavax (NVAX) Expected to Announce Earnings on Thursday

Novavax (NASDAQ:NVAX) is projected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $90.2580 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Novavax Price Performance

NASDAQ NVAX opened at $8.69 on Thursday. Novavax has a 12-month low of $5.01 and a 12-month high of $10.64. The firm’s fifty day simple moving average is $7.90 and its two-hundred day simple moving average is $7.94. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93. The firm has a market capitalization of $1.41 billion, a P/E ratio of 4.85 and a beta of 2.58.

Institutional Investors Weigh In On Novavax

Several hedge funds have recently bought and sold shares of the stock. Quarry LP purchased a new position in shares of Novavax during the 3rd quarter valued at approximately $33,000. State of Wyoming acquired a new stake in Novavax during the second quarter valued at $52,000. Danske Bank A S purchased a new position in Novavax in the third quarter valued at $64,000. Dimensional Fund Advisors LP purchased a new position in Novavax in the fourth quarter valued at $75,000. Finally, Williams Jones Wealth Management LLC. acquired a new position in shares of Novavax in the fourth quarter worth about $77,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

NVAX has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. TD Cowen decreased their price objective on shares of Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. JPMorgan Chase & Co. dropped their target price on shares of Novavax from $7.00 to $6.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 18th. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, HC Wainwright lifted their price objective on shares of Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.25.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.